PARIS (Reuters) -The board of directors of the pharmaceutical laboratory Sanofi on Sunday recorded the entry into exclusive negotiations with the American fund Clayton Dubilier & Rice (CD&R) for the sale of 51% of its subsidiary Opella, the manufacturer of Doliprane, reports Le Figaro without citing its sources.
As part of this transaction and under a tripartite agreement with Sanofi and CD&R, the French State will take a 1% stake in Opella through the public investment bank Bpifrance, declared Sunday evening in journalists the office of the Minister of Economy and Finance, Antoine Armand.
This participation, worth an estimated 150 million euros, was mentioned this week by the French government to allay concerns raised by this operation, particularly in terms of jobs in the company’s French factories.
Sanofi, which did not immediately respond to requests from Reuters, should not communicate publicly on the subject until Monday morning after having informed staff representatives of the decision of its board of directors, indicates Le Figaro.
(Written by Tangi Salaün, with Juliette Jabkhiro and Dominique Patton)
Copyright © 2024 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
